Skip to Content

    Genetic testing is having a heyday as the process of sequencing genomes becomes cheaper and more ubiquitous. Illumina has capitalized with its testing expertise. It partners with consumer-focused DNA testing services like 23andMe, and with pharma giants like Bristol-Myers Squibb who seek its help with drug development. Last year, the FDA approved Illumina’s companion diagnostic for Amgen’s Vectibix, a drug for metastatic colorectal cancer. In the past 12 months, Illumina has provided a 60% return to shareholders; over the past five years, that figure is 306%.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score2.7
    Health Care
    Life Sciences Tools and Services
    Francis A. deSouza
    HQ Location
    San Diego
    Revenues ($M) (Past 12 Months)$3,104
    Profits ($M) (Past 12 Months)$648
    Market Value as of Oct. 10, 2018 ($M)$44,800